Basch, E., Iasonos, A., McDonough, T., Barz, A., Culkin, A., Kris, M.G. and Schrag, D. (2006) Patient versus Clinician Symptom Reporting Using the National Cancer Institute Common Terminology Criteria for Adverse Events. Lancet Oncology, 7, 903-909.
https://doi.org/10.1016/S1470-2045(06)70910-X

has been cited by the following article:

• TITLE: Experimental Therapeutic Trial of an Antibody against the Cell Adhesion Molecule Gicerin for Lymphomas Using a Murine Cell Line

  AUTHORS: Yasuhiro Tsukamoto, Yukiko Miyagawa, Osamu Maeda

  KEYWORDS: Gicerin, Cell Adhesion Molecule, Lymphoma, Mouse

  JOURNAL NAME: Journal of Cancer Therapy, Vol.9 No.10, October 15, 2018

  ABSTRACT: Chemotherapy, occasionally combined with radiotherapy, is a major method for treating lymphoma but frequently produces side-effects in patients. Thus, novel therapeutics should be developed as an alternative the chemotherapy in lymphoma patients. Although the cell adhesion molecule gicerins are almost entirely absent in most mature tissues, except for muscle and endothelial cells, various neoplastic cells strongly express gicerin in their cell membranes. This suggests the potential function of gicerin in the progression of tumors, including tumor growth, invasion and metastasis to distant organs from primary sites. In the present study, we assessed therapeutic effects of anti-gicerin antibodies on the murine lymphoma cell line YAC1. Gicerin was found to be expressed in the cell membrane of YAC1 cells and promoted the cell adhesion activity of the YAC1 cells on HUVECs, an endothelial cell line. In addition, YAC1 cells were implanted sub-cutaneously in mice in order to examine the therapeutic effects of anti-gicerin antibodies on lymphoma progression in vivo. The anti-gicerin antibodies suppressed and reduced the lymphoma tumor growth in the mice, whereas the growth of tumor mass was not inhibited by pre-immune IgG administrations. YAC1 cells were also implanted intravenously in mice in order to examine the effects of anti-gicerin antibodies on the pulmonary metastasis of lymphoma cells. The metastasis of the YAC1 cells to the lungs was inhibited by the injection of anti-gicerin antibodies. These findings indicate that anti-gicerin antibodies inhibit the progression of prednisolone-resistant lymphoma, making this a promising novel therapeutic method for treating refractory lymphoma cases.